Skip to main content

09.11.2017 | Original Article | Ausgabe 2/2018

Comparative Clinical Pathology 2/2018

In vitro analysis of antispasmodic activity of ethanolic stem extracts of Uvaria rufa Blume and Anomianthus dulcis (Dunal) J. Sinclair on excised rat’s ileum

Comparative Clinical Pathology > Ausgabe 2/2018
Chattida Wiya, Kanokporn Saenphet, Supap Saenphet, Wararut Buncharoen


Irritable bowel syndrome (IBS) is a symptom of functional gastrointestinal disorders. It is commonly experienced as abdominal cramp, diarrhea, and constipation. The diagnosis and treatment of IBS were mostly conducted by synthetic medicines including antispasmodic drugs that have many side effects and are so expensive. The aim of the present study was to explore the antispasmodic activity of Uvaria rufa Blume and Anomianthus dulcis (Dunal) J. Sinclair extracts on isolated rats’ ilia which later compared to atropine as reference drug. The ethanolic extracts from the stem of A. dulcis and U. rufa were investigated for their antispasmodic activities against acetylcholine-induced rats’ ilia contraction in vitro experiment. The results of this study showed that both ethanolic extracts of U. rufa and A. dulcis have an antispasmodic efficiency at all concentrations of 200, 300, 400, and 500 μg/ml on excised rats’ ilia. They produced the highest relaxation of 92.71 ± 5.97 and 98.53 ± 0.61% in A. dulcis and U. rufa extracts, respectively, while atropine produced 112.84 ± 5.61% at concentration of 10.0 μg/ml. These results suggest that U. rufa and A. dulcis could be used as antispasmodic agents for IBS treatment.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Für Ihren Erfolg in Klinik und Praxis - Die beste Hilfe in Ihrem Arbeitsalltag als Mediziner*in

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Über diesen Artikel

Weitere Artikel der Ausgabe 2/2018

Comparative Clinical Pathology 2/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

14.10.2021 | Prostatakarzinom | CME | Ausgabe 6/2021

Das lokalisierte Prostatakarzinom

05.10.2021 | Nierenkarzinom | Schwerpunkt: Nierenturmoren | Ausgabe 6/2021

SMARCB1(INI1)-defizientes Nierenzellkarzinom: medullär und darüber hinaus

Neue Konzepte

22.09.2021 | Schwerpunkt: Nierentumoren | Ausgabe 6/2021

Eosinophiles solide und zystisches Nierenzellkarzinom (ESC-NZK)

01.09.2021 | Nierenkarzinom | Schwerpunkt: Nierentumoren | Ausgabe 6/2021

Onkozytäre Tumoren der Niere – neue Differenzialdiagnosen